SHUKRA PHARMACEUTICALS
|
SHUKRA PHARMACEUTICALS Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 16.94 | 11.26 | 4.79 | 1.20 | 0.23 |
| CEPS(Rs) | 4.70 | 3.99 | 0.80 | 0.55 | 0.50 |
| DPS(Rs) | 1.00 | 0.50 | 0.50 | - | - |
| Book NAV/Share(Rs) | 52.67 | 64.63 | 104.43 | 99.63 | 98.43 |
| Tax Rate(%) | 6.77 | 0.79 | 26.26 | -92.33 | 79.16 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 26.02 | 9.12 | 14.09 | 12.90 | 11.22 |
| EBIT Margin(%) | 27.05 | 8.03 | 6.37 | 1.17 | 1.26 |
| Pre Tax Margin(%) | 26.66 | 7.55 | 4.97 | 0.87 | 1.24 |
| PAT Margin (%) | 24.86 | 7.49 | 3.66 | 1.68 | 0.26 |
| Cash Profit Margin (%) | 27.61 | 10.61 | 11.78 | 14.84 | 11.02 |
| Performance Ratios | |||||
| ROA(%) | 24.26 | 8.01 | 2.12 | 0.54 | 0.11 |
| ROE(%) | 44.70 | 21.16 | 4.70 | 1.21 | 0.23 |
| ROCE(%) | 44.24 | 18.85 | 5.79 | 0.54 | 0.77 |
| Asset Turnover(x) | 0.98 | 1.07 | 0.58 | 0.32 | 0.44 |
| Sales/Fixed Asset(x) | 1.84 | 1.58 | 0.60 | 0.34 | 0.46 |
| Working Capital/Sales(x) | 1.77 | 5.57 | 5.86 | 1.24 | 1.84 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.54 | 0.63 | 1.67 | 2.91 | 2.19 |
| Receivable days | 133.87 | 116.60 | 152.77 | 288.50 | 176.69 |
| Inventory Days | 13.39 | 22.06 | 50.20 | 50.01 | 22.02 |
| Payable days | 167.55 | 170.00 | 245.53 | 761.94 | 562.70 |
| Valuation Parameters | |||||
| PER(x) | 4.82 | 1.04 | 2.62 | 7.71 | 42.79 |
| PCE(x) | 17.36 | 2.94 | 3.92 | 4.19 | 4.84 |
| Price/Book(x) | 6.20 | 0.73 | 0.58 | 0.45 | 0.47 |
| Yield(%) | 0.31 | 1.07 | 0.83 | - | - |
| EV/Net Sales(x) | 4.70 | 0.33 | 0.61 | 1.45 | 1.29 |
| EV/Core EBITDA(x) | 15.78 | 2.97 | 4.23 | 9.02 | 9.84 |
| EV/EBIT(x) | 17.38 | 4.12 | 9.61 | 123.83 | 88.17 |
| EV/CE(x) | 5.77 | 0.64 | 0.64 | 0.64 | 0.65 |
| M Cap / Sales | 4.79 | 0.31 | 0.46 | 0.62 | 0.62 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 26.75 | 187.19 | 82.97 | -5.49 | 109.31 |
| Core EBITDA Growth(%) | 238.70 | 121.12 | 64.81 | 16.13 | -8.15 |
| EBIT Growth(%) | 327.07 | 261.99 | 895.12 | -24.17 | -76.15 |
| PAT Growth(%) | 320.68 | 486.99 | 299.10 | 428.31 | -92.29 |
| EPS Growth(%) | 50.47 | 134.79 | 299.10 | 428.30 | -92.29 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.05 | 0.20 | 0.21 | 0.63 | 0.52 |
| Current Ratio(x) | 3.97 | 1.25 | 1.28 | 2.28 | 2.07 |
| Quick Ratio(x) | 3.81 | 1.17 | 0.96 | 2.04 | 1.87 |
| Interest Cover(x) | 70.77 | 16.82 | 4.55 | 3.94 | 84.02 |
| Total Debt/Mcap(x) | 0.01 | 0.10 | 0.36 | 1.40 | 1.10 |
Compare Financial Ratios of peers of SHUKRA PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SHUKRA PHARMACEUTICALS | ₹491.4 Cr | 21.5% | 86% | 227.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹436,103.0 Cr | 1% | 0.7% | 47.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹153,540.0 Cr | -1.1% | -5.8% | 61.7% | Stock Analytics | |
| CIPLA | ₹119,196.0 Cr | 0.3% | -1.8% | 19.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,752.0 Cr | 6% | 11.8% | 20.3% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹97,041.2 Cr | -1.5% | -0.1% | 47% | Stock Analytics | |
SHUKRA PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SHUKRA PHARMACEUTICALS | 21.5% |
86% |
227.7% |
| SENSEX | -2.7% |
-0.8% |
9.9% |
You may also like the below Video Courses
